JP2005503766A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005503766A5 JP2005503766A5 JP2002576654A JP2002576654A JP2005503766A5 JP 2005503766 A5 JP2005503766 A5 JP 2005503766A5 JP 2002576654 A JP2002576654 A JP 2002576654A JP 2002576654 A JP2002576654 A JP 2002576654A JP 2005503766 A5 JP2005503766 A5 JP 2005503766A5
- Authority
- JP
- Japan
- Prior art keywords
- cryptovirus
- seq
- antibody
- nucleotide positions
- degenerate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000405758 Betapartitivirus Species 0.000 claims 70
- 238000000034 method Methods 0.000 claims 63
- 239000002773 nucleotide Substances 0.000 claims 57
- 125000003729 nucleotide group Chemical group 0.000 claims 57
- 210000004027 cell Anatomy 0.000 claims 31
- 239000000523 sample Substances 0.000 claims 31
- 108020004707 nucleic acids Proteins 0.000 claims 25
- 102000039446 nucleic acids Human genes 0.000 claims 25
- 150000007523 nucleic acids Chemical class 0.000 claims 25
- 102000004169 proteins and genes Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 230000000295 complement effect Effects 0.000 claims 17
- 239000012620 biological material Substances 0.000 claims 16
- 108091026890 Coding region Proteins 0.000 claims 12
- 239000002245 particle Substances 0.000 claims 11
- 230000000840 anti-viral effect Effects 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 210000002845 virion Anatomy 0.000 claims 9
- 101710091045 Envelope protein Proteins 0.000 claims 8
- 101710188315 Protein X Proteins 0.000 claims 8
- 102100021696 Syncytin-1 Human genes 0.000 claims 8
- 239000012736 aqueous medium Substances 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 8
- 108010078321 Guanylate Cyclase Proteins 0.000 claims 7
- 102000014469 Guanylate cyclase Human genes 0.000 claims 7
- 230000001413 cellular effect Effects 0.000 claims 7
- 238000012258 culturing Methods 0.000 claims 7
- 210000002919 epithelial cell Anatomy 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 229940126585 therapeutic drug Drugs 0.000 claims 7
- 238000010171 animal model Methods 0.000 claims 6
- 238000003556 assay Methods 0.000 claims 6
- 230000027455 binding Effects 0.000 claims 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 6
- 230000010076 replication Effects 0.000 claims 6
- 230000003612 virological effect Effects 0.000 claims 6
- 229960005486 vaccine Drugs 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 230000003321 amplification Effects 0.000 claims 4
- 230000009286 beneficial effect Effects 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims 4
- 229940043274 prophylactic drug Drugs 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 229940124598 therapeutic candidate Drugs 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 3
- 210000004962 mammalian cell Anatomy 0.000 claims 3
- 230000000626 neurodegenerative effect Effects 0.000 claims 3
- 230000000926 neurological effect Effects 0.000 claims 3
- 239000000047 product Substances 0.000 claims 3
- 239000011541 reaction mixture Substances 0.000 claims 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical group C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 241000283984 Rodentia Species 0.000 claims 2
- 239000013599 cloning vector Substances 0.000 claims 2
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000012750 in vivo screening Methods 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000008771 Lymphadenopathy Diseases 0.000 claims 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 239000012881 co-culture medium Substances 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 230000001759 immunoprophylactic effect Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 208000018555 lymphatic system disease Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 150000002823 nitrates Chemical class 0.000 claims 1
- 239000002840 nitric oxide donor Substances 0.000 claims 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical class CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims 1
- GSKDBLIBBOYOFU-UHFFFAOYSA-N oxadiazol-5-amine Chemical class NC1=CN=NO1 GSKDBLIBBOYOFU-UHFFFAOYSA-N 0.000 claims 1
- VZQAQPGIOPQBGU-UHFFFAOYSA-N oxidoiminoiron(1+) Chemical class [Fe]N=O VZQAQPGIOPQBGU-UHFFFAOYSA-N 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical class SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26725301P | 2001-02-07 | 2001-02-07 | |
| PCT/US2002/004117 WO2002077211A2 (en) | 2001-02-07 | 2002-02-07 | A virus (cryptovirus) within the rubulavirus genus and uses therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005503766A JP2005503766A (ja) | 2005-02-10 |
| JP2005503766A5 true JP2005503766A5 (enExample) | 2005-12-22 |
| JP4324379B2 JP4324379B2 (ja) | 2009-09-02 |
Family
ID=23017976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002576654A Expired - Fee Related JP4324379B2 (ja) | 2001-02-07 | 2002-02-07 | ルブラウイルス（ｒｕｂｕｌａｖｉｒｕｓ）属に属するニューロビルレントウイルス（ｎｅｕｒｏｖｉｒｕｌｅｎｔ）（クリプトウイルス（ｃｒｙｐｔｏｖｉｒｕｓ））とその使用 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1373477B1 (enExample) |
| JP (1) | JP4324379B2 (enExample) |
| AT (1) | ATE517179T1 (enExample) |
| AU (2) | AU2002306472C1 (enExample) |
| CA (1) | CA2436208C (enExample) |
| WO (1) | WO2002077211A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
| FR2938841B1 (fr) * | 2008-11-21 | 2010-12-17 | Centre Nat Rech Scient | Proteines mutantes de la proteine f de piv-5 et de piv-2 |
| FR2938840B1 (fr) * | 2008-11-21 | 2010-12-17 | Centre Nat Rech Scient | Proteines mutantes de la proteine f de piv-5 et de piv-2 |
| WO2011150320A2 (en) * | 2010-05-27 | 2011-12-01 | University Of Georgia Research Foundation, Inc. | Activators of innate immunity |
| CN113481185B (zh) * | 2021-08-05 | 2022-12-02 | 云南师范大学 | 一种耐盐β-半乳糖苷酶GalNC2-13及其制备方法和应用 |
| WO2025076466A2 (en) * | 2023-10-06 | 2025-04-10 | Cyanvac Llc | Piv5-based vaccines with modified antigen: methods of making and using the same |
-
2002
- 2002-02-07 WO PCT/US2002/004117 patent/WO2002077211A2/en not_active Ceased
- 2002-02-07 AU AU2002306472A patent/AU2002306472C1/en not_active Ceased
- 2002-02-07 AT AT02753754T patent/ATE517179T1/de not_active IP Right Cessation
- 2002-02-07 JP JP2002576654A patent/JP4324379B2/ja not_active Expired - Fee Related
- 2002-02-07 CA CA2436208A patent/CA2436208C/en not_active Expired - Fee Related
- 2002-02-07 EP EP02753754A patent/EP1373477B1/en not_active Expired - Lifetime
-
2008
- 2008-06-06 AU AU2008202524A patent/AU2008202524A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115710311A (zh) | 冠状病毒的抗体或其抗原结合片段 | |
| Wichmann et al. | Hantaan virus infection causes an acute neurological disease that is fatal in adult laboratory mice | |
| Omura et al. | Role of outer capsid proteins in transmission of Phytoreovirus by insect vectors | |
| CN116023478A (zh) | 冠状病毒的中和抗体或其抗原结合片段 | |
| CN118777611A (zh) | 病毒感染的诊断和治疗 | |
| WO2022017124A1 (zh) | 具有广谱中和活性的抗亨尼帕病毒单克隆抗体及应用 | |
| JPH06506823A (ja) | ノーワーク及び関連のウィルスを検出し同定するための方法と試薬 | |
| KR20020008069A (ko) | 진단 분석법 | |
| JP2005503766A5 (enExample) | ||
| Tamura et al. | Pathogenesis of Hantaan virus in mice | |
| JP3061258B2 (ja) | 非ａ非ｂ非ｃ非ｄ非ｅ型肝炎試薬及びそれらの使用方法 | |
| Escoffier et al. | Infection of chicken embryonic fibroblasts by measles virus: adaptation at the virus entry level | |
| CN105671004A (zh) | 一种培养戊型肝炎病毒的方法 | |
| Chen et al. | Construction and characterization of an improved DNA-launched infectious clone of duck hepatitis a virus type 1 | |
| CN118373906B (zh) | 抗发热伴血小板减少综合征病毒人源中和抗体及应用 | |
| JP2004515215A5 (enExample) | ||
| JP4324379B2 (ja) | ルブラウイルス（ｒｕｂｕｌａｖｉｒｕｓ）属に属するニューロビルレントウイルス（ｎｅｕｒｏｖｉｒｕｌｅｎｔ）（クリプトウイルス（ｃｒｙｐｔｏｖｉｒｕｓ））とその使用 | |
| JP7414225B2 (ja) | ＳＡＲＳ－ＣｏＶ－２結合ペプチド | |
| CN110462030A (zh) | 强毒性肠道病毒71的稳定生产及其利用 | |
| Guo et al. | Construction of the Vero cell culture system that can produce infectious HCV particles | |
| JP2004511208A5 (enExample) | ||
| CN116710478A (zh) | 冠状病毒感染性细胞及其制备方法 | |
| CN111533791B (zh) | 一种钩端螺旋体黏附蛋白rvWFA3-2的制备方法和应用 | |
| JP2010268688A (ja) | エンテロウイルス７１受容体を用いたウイルス感染系 | |
| KR101122244B1 (ko) | 효율적으로 복제할 수 있는 변이 c형 간염 바이러스, 리포터 유전자를 포함하는 변이 c형 간염 바이러스, 상기 변이 c형 간염 바이러스를 이용한 c형 간염 바이러스 백신 제조방법 및 상기 변이 c형 간염 바이러스를 이용한 항c형 간염 바이러스 조성물의 스크리닝 방법 |